2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on …
Abstract Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …
2022 AHA/ACC/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology/American Heart Association …
Aim: The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure” replaces
the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the “2017 …
the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the “2017 …
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic …
AR Lyon, T Lopez-Fernandez, LS Couch… - European Heart …, 2022 - academic.oup.com
ESC Guidelines e341 (1) the specific situation of the patient. In this respect, it is specified
that, unless otherwise provided for by national regulations, offlabel use of medication should …
that, unless otherwise provided for by national regulations, offlabel use of medication should …
[HTML][HTML] Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations
G Curigliano, D Lenihan, M Fradley, S Ganatra… - Annals of …, 2020 - Elsevier
Cancer and cardiovascular (CV) disease are the most prevalent diseases in the developed
world. Evidence increasingly shows that these conditions are interlinked through common …
world. Evidence increasingly shows that these conditions are interlinked through common …
Pre-activated nanoparticles with persistent luminescence for deep tumor photodynamic therapy in gallbladder cancer
S Juengpanich, S Li, T Yang, T Xie, J Chen… - Nature …, 2023 - nature.com
Phototherapy of deep tumors still suffers from many obstacles, such as limited near-infrared
(NIR) tissue penetration depth and low accumulation efficiency within the target sites …
(NIR) tissue penetration depth and low accumulation efficiency within the target sites …
The Role of Cardioprotection in Cancer Therapy Cardiotoxicity: JACC: CardioOncology State-of-the-Art Review
Cardiotoxicity is a relatively frequent and potentially serious side effect of traditional and
targeted cancer therapies. Both general measures and specific pharmacologic …
targeted cancer therapies. Both general measures and specific pharmacologic …
Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies
N Dempsey, A Rosenthal, N Dabas… - Breast Cancer Research …, 2021 - Springer
Purpose Despite great success as a targeted breast cancer therapy, trastuzumab use may
be complicated by heart failure and loss of left ventricular contractile function. This review …
be complicated by heart failure and loss of left ventricular contractile function. This review …
Cardiotoxicity of anticancer drugs: Molecular mechanisms and strategies for cardioprotection
MB Morelli, C Bongiovanni, S Da Pra… - Frontiers in …, 2022 - frontiersin.org
Chemotherapy and targeted therapies have significantly improved the prognosis of
oncology patients. However, these antineoplastic treatments may also induce adverse …
oncology patients. However, these antineoplastic treatments may also induce adverse …
Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): extended follow-up of a 2× 2 factorial, randomized, placebo-controlled, double …
SL Heck, A Mecinaj, AH Ree, P Hoffmann… - Circulation, 2021 - Am Heart Assoc
Background: Adjuvant breast cancer therapy containing anthracyclines with or without anti–
human epidermal growth factor receptor–2 antibodies and radiotherapy is associated with …
human epidermal growth factor receptor–2 antibodies and radiotherapy is associated with …
2022 ACC/AHA/HFSA guideline for the management of heart failure
ABSTRACT Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …